Sodium triacetoxyborohydride → 2-Oxo-1-[2-(4-{[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methyl]amino)piperidin-1-yl)ethyl]-1,2-dihydroquinoxaline-6-carbonitrile
Reaction equation
[NH2:1][CH:2]1[CH2:7][CH2:6][N:5]([CH2:8][CH2:9][N:10]2[C:19]3[C:14](=[CH:15][C:16]([C:20]#[N:21])=[CH:17][CH:18]=3)[N:13]=[CH:12][C:11]2=[O:22])[CH2:4][CH2:3]1.[O:23]=[C:24]1[CH2:29][O:28][C:27]2[CH:30]=[CH:31][C:32]([CH:34]=O)=[N:33][C:26]=2[NH:25]1.[BH-](OC(C)=O)(OC(C)=O)OC(C)=O.[Na+]>>[O:22]=[C:11]1[CH:12]=[N:13][C:14]2[C:19](=[CH:18][CH:17]=[C:16]([C:20]#[N:21])[CH:15]=2)[N:10]1[CH2:9][CH2:8][N:5]1[CH2:6][CH2:7][CH:2]([NH:1][CH2:34][C:32]2[CH:31]=[CH:30][C:27]3[O:28][CH2:29][C:24](=[O:23])[NH:25][C:26]=3[N:33]=2)[CH2:3][CH2:4]1Participants
4
Reactant 3
Product 1
Procedure
1-[2-(4-Aminopiperidin-1-yl)ethyl]-2-oxo-1,2-dihydroquinoxaline-6-carbonitrile (Intermediate 197, 0.125 g) was reacted with 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine-6-carbaldehyde (WO 2004/058144) (0.17 g) and NaBH(OAc)3 (0.27 g) as described for Example 107. The residue was purified by reverse phase HPLC with acetonitrile in water containing 0.1% TFA. Fractions containing product were concentrated to remove acetonitrile, neutralized with Na2CO3 solid, extracted with ethyl acetate, dried (Na2SO4), filtered and concentrated. The residue was suspended in diethyl ether and filtered to yield 127 mg of a colorless solid.
Workup
- customThe residue was purified by reverse phase HPLC with acetonitrile in water containing 0.1% TFA
- additionFractions containing product
- concentrationwere concentrated
- customto remove acetonitrile
- extractionextracted with ethyl acetate
- dry with materialdried (Na2SO4)
- filtrationfiltered
- concentrationconcentrated
- filtrationfiltered
Sources & evidence
- ORD record
- ord-d7898e55c36141a39482080ff0332efd
- Source dataset
- uspto-grants-2012_02
- Patent number
- US08124602B2
Reaction notes
Loading…